Please assess the completion status of the following clinical trial:

Trial Title: Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had an ischemic stroke believed to be due to small vessel disease, large vessel cervical or intracranial atherosclerosis within the past 10 days~* Subject is willing and able to undergo study requirements and expected to be geographically stable during study follow-up~* Subject is 60 years of age or older, or age 50 to 59 years plus a documented medical history of at least one of the following additional risk factors for stroke:~  * Congestive heart failure~ * Hypertension (Systolic Blood Pressure \> 140)~ * Diabetes Mellitus~ * Prior Stroke (\>90 days ago, other than study qualifying index event)~ * Vascular disease (e.g. coronary artery disease, heart attack, peripheral artery disease and complex aortic plaque)~Exclusion Criteria:~* Subject has had a cryptogenic stroke~* Subject has had a cardioembolic stroke~* Subject has untreated hyperthyroidism~* Subject has had a recent myocardial infarction \<1 month of stroke~* Subject has had a recent cardiac surgery (e.g. coronary artery bypass surgery (CABG)) \<1 month of stroke~* Subject has a mechanical heart valve~* Subject has valvular disease requiring immediate surgical intervention~* Subject has documented prior history of atrial fibrillation or atrial flutter~* Subject has permanent indication for oral anticoagulation~* Subject has permanent contraindication to oral anticoagulation such that detection of AF would not change medical management, based on enrolling investigators judgment~* Subject is enrolled in a concurrent study that may confound the results of this study. Co-enrollment in any concurrent clinical study (including registries) requires approval of the study manager or designee.~* Subject's life expectancy is less than 1 year~* Subject is pregnant~* Subject has or is indicated for implant with a pacemaker, Implantable Cardioverter Defibrillator (ICD), Cardiac ResynchronizationTherapy (CRT), or an implantable hemodynamic monitor~* Subject with a medical condition that precludes the patient from participation in the opinion of the investigator

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reveal LINQ™ Insertable Cardiac Monitor (Type: ACTIVE_COMPARATOR): Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
- Control Arm (Type: NO_INTERVENTION): Subjects randomized to the control arm will be followed per site specific standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).